Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-111928-22fc607c",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n# TREM2 Receptor Modulation Synthesis Analysis\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": \"H3\",\n      \"hypothesis_name\": \"SYK Inhibition Downstream of TREM2\",\n      \"target\": \"SYK\",\n      \"composite_score\": 0.63,\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.82,\n        \"evidence_strength\": 0.75,\n        \"novelty\": 0.35,\n        \"feasibility\": 0.78,\n        \"therapeutic_potential\": 0.68,\n        \"druggability\": 0.82,\n        \"safety_profile\": 0.58,\n        \"competitive_landscape\": 0.52,\n        \"data_availability\": 0.72,\n        \"reproducibility\": 0.68\n      },\n      \"evidence_for\": [\n        {\n          \"claim\": \"SYK is the obligate downstream kinase for TREM2-TYROBP signaling\",\n          \"pmid\": \"28935867\"\n        },\n        {\n          \"claim\": \"Fostamatinib (SYK inhibitor) is FDA-approved for ITP with acceptable safety profiles\",\n          \"pmid\": \"29053630\"\n        },\n        {\n          \"claim\": \"SYK has shorter signaling half-life than receptor activation, enabling rapid on/off control\",\n          \"pmid\": \"30048316\"\n        },\n        {\n          \"claim\": \"SYK inhibitors cross blood-brain barrier (clinical data in neurological indications)\",\n          \"pmid\": \"29053630\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"SYK inhibitors have off-target toxicity due to broad SYK expression across immune cell types\",\n          \"pmid\": \"29053630\"\n        },\n        {\n          \"claim\": \"Complete SYK inhibition may impair beneficial microglial surveillance functions\",\n          \"pmid\": \"28935867\"\n        }\n      ],\n      \"synthesis_notes\": \"Strongest practical hypothesis. Fostamatinib already approved; enables therapeutic tuning of microglial activation without direct receptor manipulation. Key challenge: achieving CNS-penetrant selectivity for microglial SYK while sparing peripheral immune function.\",\n      \"confidence_practical_translation\": 0.72\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": \"H5\",\n      \"hypothesis_name\": \"PLCγ2 Selective Activation Bypass\",\n      \"target\": \"PLCG2\",\n      \"composite_score\": 0.50,\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.62,\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.72,\n        \"feasibility\": 0.38,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.28,\n        \"safety_profile\": 0.42,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.48,\n        \"reproducibility\": 0.58\n      },\n      \"evidence_for\": [\n        {\n          \"claim\": \"PLCγ2 is the obligate downstream effector of TREM2/TYROBP\",\n          \"pmid\": \"29229958\"\n        },\n        {\n          \"claim\": \"PLCγ2 activating mutations cause constitutive activation without receptor input\",\n          \"pmid\": \"29229958\"\n        },\n        {\n          \"claim\": \"PLCγ2 SH2 domain structures enable allosteric activator design\",\n          \"pmid\": \"29229958\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"No direct PLCγ2 activators exist in literature or clinical pipelines\",\n          \"pmid\": \"29229958\"\n        },\n        {\n          \"claim\": \"Enzyme activation carries higher safety risk than inhibition (uncontrolled signaling)\",\n          \"pmid\": \"292",
  "tokens_used": "814",
  "persona_id": "persona-synthesizer"
}